Consensus Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2025-12-12 am EST			After hours 01:31:30 pm
83.32 ^EUR	-0.38%		83.06	-0.31%

09:27am	European health regulator recommends approval for GSK's twice-yearly asthma drug	RE
06:00am	India, France seal treaty revamp giving Paris dividend relief, Delhi tax rights	RE

Evolution of the Average Target: Sanofi

Evolution of the Target Price: Sanofi

Changes in Analyst Recommendations: Sanofi

752bd23d342906.7d0fMDsI2jeLTOpqHvm0tMpJB7CyHjMeGdBdANQw-wU.lI9sZw5jtQPOJowLbZ7h_f94Q_bGb1FrTpMUNItStzGosk1ZQ3izR_h_hQ~90b7da5545b3228af6f4f30e9ad6c60f

Analysts' recommendations: Sanofi

Dec. 09	Guggenheim Downgrades Sanofi to Neutral From Buy	MT
Dec. 08	SANOFI : JP Morgan is Neutral	ZD
Dec. 05	SANOFI : Buy rating from Bernstein	ZD
Nov. 25	SANOFI : Deutsche Bank reiterates its Buy rating	ZD
Nov. 19	SANOFI : Buy rating from Jefferies	ZD
Nov. 07	Sanofi Announces Positive Results from the pivotal LIBERTY- AFRS-AIMS Phase 3 Study	CI
Nov. 07	Regeneron, Sanofi Say Dupixent for Allergic Fungal Rhinosinusitis Met Primary Endpoint in Phase 3 Study	MT
Nov. 07	Sanofi, Regeneron's Dupixent Hits Key Goals in Late-Stage Fungal Allergy Trial	DJ
Nov. 07	Sanofi's Dupixent Achieves Phase 3 Success in Allergic Fungal Rhinosinusitis
Nov. 07	Sanofi and Regeneron's Dupixent meets endpoints, accepted for priority review by FDA	RE
Nov. 07	Berenberg Upbeat on Sanofi's Top Line Growth, R&D Turnaround	MT
Oct. 30	SANOFI : Deutsche Bank reaffirms its Buy rating	ZD
Oct. 28	SANOFI : Goldman Sachs gives a Neutral rating	ZD
Oct. 27	SANOFI : Deutsche Bank gives a Buy rating	ZD
Oct. 27	UBS remains bullish on Sanofi after quarterly results.
Oct. 27	SANOFI : Receives a Buy rating from Jefferies	ZD
Oct. 27	SANOFI : UBS reiterates its Buy rating	ZD
Oct. 24	SANOFI : DZ Bank keeps its Buy rating	ZD
Oct. 24	SANOFI : Investors expect a home run now; earnings beat may not suffice
Oct. 24	SANOFI : Receives a Buy rating from UBS	ZD
Oct. 24	SANOFI : JP Morgan remains its Buy rating	ZD
Oct. 24	SANOFI : Bernstein reiterates its Buy rating	ZD
Oct. 24	SANOFI : Jefferies remains its Buy rating	ZD
Oct. 22	SANOFI : JP Morgan reiterates its Buy rating	ZD
Oct. 22	Sanofi's Efdoralprin Alfa met all primary and key secondary endpoints	RE

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SANOFI					+25.78%
	ELI LILLY AND COMPANY					+6.57%
	JOHNSON & JOHNSON					-1.89%
	ABBVIE INC.					+9.35%
	ROCHE HOLDING AG					+1.69%
	ASTRAZENECA PLC					+10.31%
	NOVARTIS AG					+1.42%
	MERCK & CO., INC.					+8.46%
	NOVO NORDISK A/S					+23.02%
	AMGEN INC.					+2.97%
	Average					+8.77%
	Weighted average by Cap.					+6.78%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

83.64EUR

Average target price

105.20EUR

Spread / Average Target

+25.78%

High Price Target

119.00EUR

Spread / Highest target

+42.28%

Low Price Target

95.00EUR

Spread / Lowest Target

+13.58%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Guggenheim
JPMORGAN	Richard Vosser
BERNSTEIN RESEARCH	Florent Cespedes
JEFFERIES
GOLDMAN SACHS	James Quigley
alphavalue	Abhishek Raval
UBS	Matthew Weston
DZ BANK	Elmar Kraus
DEUTSCHE BANK RESEARCH	Emmanuel Papadakis
BERENBERG	Luisa Hector
Intron Health
Morgan Stanley
AlphaValue/Baader Europe
BARCLAYS	Emily Field
Berenberg Bank
CIC Market Solutions
STIFEL	Eric Le Berrigaud
CREDIT SUISSE	Dominic Lunn
Argus
Kepler Cheuvreux
DEUTSCHE BANK	Emmanuel Papadakis
Stifel Nicolaus
Liberum Capital
SVB Leerink
BAADER BANK
Deutsche Bank Securities
ODDO BHF
HSBC	Julie Mead
BANK OF AMERICA (BOFA)	Sachin Jain